GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuren Pharmaceuticals Ltd (ASX:NEU) » Definitions » Free Cash Flow per Share

Neuren Pharmaceuticals (ASX:NEU) Free Cash Flow per Share : A$0.83 (TTM As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Neuren Pharmaceuticals Free Cash Flow per Share?

Neuren Pharmaceuticals's Free Cash Flow per Share for the six months ended in Jun. 2024 was A$-0.24. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was A$0.83.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Neuren Pharmaceuticals was 94.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the FCF Growth Rate using Free Cash Flow per Share data.

The historical rank and industry rank for Neuren Pharmaceuticals's Free Cash Flow per Share or its related term are showing as below:

During the past 13 years, Neuren Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 62.80% per year. The lowest was -44.90% per year. And the median was 9.40% per year.

ASX:NEU's 3-Year FCF Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.9
* Ranked among companies with meaningful 3-Year FCF Growth Rate only.

Neuren Pharmaceuticals Free Cash Flow per Share Historical Data

The historical data trend for Neuren Pharmaceuticals's Free Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuren Pharmaceuticals Free Cash Flow per Share Chart

Neuren Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Free Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.12 -0.08 -0.09 0.03 1.44

Neuren Pharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Free Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 0.08 0.35 1.07 -0.24

Competitive Comparison of Neuren Pharmaceuticals's Free Cash Flow per Share

For the Biotechnology subindustry, Neuren Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuren Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Neuren Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Neuren Pharmaceuticals Free Cash Flow per Share Calculation

Free Cashflow per Share is the amount of Free Cashflow per outstanding share of the company's stock.

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Note: GuruFocus does not calculate Free Cash Flow Per Share when Capital Expenditure is 0.

Neuren Pharmaceuticals's Free Cash Flow Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Free Cash Flow Per Share(A: Dec. 2023 )
=(Cash Flow from Operations+Capital Expenditure)/Shares Outstanding (Diluted Average)
=(188.229+-0.04)/130.792
=188.189/130.792
=1.44

Neuren Pharmaceuticals's Free Cash Flow Per Share for the quarter that ended in Jun. 2024 is calculated as

Free Cash Flow Per Share(Q: Jun. 2024 )
=(Cash Flow from Operations+Capital Expenditure)/Shares Outstanding (Diluted Average)
=(-30.927+-0.005)/130.767
=-30.932/130.767
=-0.24

Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuren Pharmaceuticals  (ASX:NEU) Free Cash Flow per Share Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Dec23, Neuren Pharmaceuticals's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Dec23)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/24.97+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


Neuren Pharmaceuticals Free Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Neuren Pharmaceuticals's Free Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuren Pharmaceuticals Business Description

Traded in Other Exchanges
Address
697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.

Neuren Pharmaceuticals Headlines